ENSEM Therapeutics
ENSEM Therapeutics is a drug discovery and development company focused on oncology precision medicines using its proprietary Kinetic Ensemble® platform. The company integrates AI, computational methods, and experimental techniques to identify cryptic binding pockets on difficult-to-drug targets, accelerating structure-based drug design. ENSEM aims to expand the druggable target universe by discovering unique cryptic pockets for therapeutic intervention. The company has a world-class leadership team with extensive experience in drug discovery, biology, chemistry, and clinical development, positioning it well in the oncology biotech market.
ENSEM Therapeutics
ENSEM Therapeutics is a drug discovery and development company focused on oncology precision medicines using its proprietary Kinetic Ensemble® platform. The company integrates AI, computational methods, and experimental techniques to identify cryptic binding pockets on difficult-to-drug targets, accelerating structure-based drug design. ENSEM aims to expand the druggable target universe by discovering unique cryptic pockets for therapeutic intervention. The company has a world-class leadership team with extensive experience in drug discovery, biology, chemistry, and clinical development, positioning it well in the oncology biotech market.
TL;DR
Sector: Biotechnology — small-molecule oncology precision medicines
Founded: 2021
Headquarters: Medford/Waltham, Massachusetts
Platform: Proprietary Kinetic Ensemble® platform (AI + computational + experimental)
Notable program: ETX-636 (allosteric, mutant-selective PI3Kα inhibitor/degrader)
Funding: Series A announced Oct 23, 2023; investors include MegaRobo, Legend Star, Boquan Capital
Company Overview
Problem Domain
Difficult-to-drug oncology targets and precision small-molecule therapeutics
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
Series A announced Oct 23, 2023; investors associated with company include MegaRobo, Legend Star, Boquan Capital and others
Investor Signal
“Backed by institutional and strategic investors (including MegaRobo, Legend Star, Boquan Capital, Mitsui & Co., GGV Capital, Pavilion Capital, CBC Group, Cenova, ABio-X)”